Reversal of tacrolimus-related hypertrophic obstructive cardiomyopathy 5 years after kidney transplant in a 6-year-old recipient.
Hypertrophic obstructive cardiomyopathy (HOCM) is an unusual but serious side-effect of tacrolimus (TAC) based immunosuppression primarily affecting pediatric patients after solid organ transplant. TAC-induced HOCM has already been described in patients after liver, bowel and heart transplant shortly after the procedure. Herein, we present the first case report of TAC-induced HOCM in a young renal transplant recipient 5 yr after renal transplant. The condition was diagnosed by ECHO and EKG and successfully treated by discontinuation of TAC followed by conversion to cyclosporine (CsA).
Jarzembowski
Tomasz M
TM
Division of Transplantation, Department of Surgery, University of Illinois at Chicago, Chicago, IL 60612, USA.
John
Eunice
E
Panaro
Fabrizio
F
Manzelli
Antonio
A
Cabrera
Antonio
A
Greco
Andreas
A
Varga
Peter
P
Sankary
Howard
H
Testa
Giuliano
G
Benedetti
Enrico
E
D000293:Adolescent; D002312:Cardiomyopathy, Hypertrophic / Q000139:chemically induced* / Q000175:diagnosis; D002648:Child; D016572:Cyclosporine / Q000627:therapeutic use; D004452:Echocardiography; D004562:Electrocardiography; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D016030:Kidney Transplantation; D008297:Male; D016559:Tacrolimus / Q000009:adverse effects* / Q000627:therapeutic use; D013997:Time Factors
D007166:Immunosuppressive Agents; D016572:Cyclosporine; D016559:Tacrolimus